Personalized Pathology & Cancer Therapy
61 – 78 of 78
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- « previous
- 1
- 2
- 3
- 4
- next »
- 2016
-
Mark
Complement inhibitor CSMD1 acts as tumor suppressor in human breast cancer
(
- Contribution to journal › Article
-
Mark
Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma
(
- Contribution to journal › Article
-
Mark
The prognostic impact of NK/NKT cell density in periampullary adenocarcinoma differs by morphological type and adjuvant treatment
(
- Contribution to journal › Article
-
Mark
Significant association and synergistic adverse prognostic effect of podocalyxin-like protein and epidermal growth factor receptor expression in colorectal cancer
(
- Contribution to journal › Article
- 2014
-
Mark
Reduced expression of ezrin in urothelial bladder cancer signifies more advanced tumours and an impaired survival: validatory study of two independent patient cohorts.
(
- Contribution to journal › Article
-
Mark
Expression and prognostic significance of the polymeric immunoglobulin receptor in epithelial ovarian cancer
(
- Contribution to journal › Article
-
Mark
Expression and prognostic significance of the polymeric immunoglobulin receptor in esophageal and gastric adenocarcinoma.
(
- Contribution to journal › Article
-
Mark
Incident urothelial cancer in the Malmö Diet and Cancer Study: cohort characteristics and further validation of ezrin as a prognostic biomarker.
(
- Contribution to journal › Article
- 2013
-
Mark
Influence of anthropometric factors on tumour biological characteristics of colorectal cancer in men and women : a cohort study
(
- Contribution to journal › Article
-
Mark
Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer.
(
- Contribution to journal › Article
- 2012
-
Mark
Validation of podocalyxin-like protein as a biomarker of poor prognosis in colorectal cancer
(
- Contribution to journal › Article
-
Mark
Gender, anthropometric factors and risk of colorectal cancer with particular reference to tumour location and TNM stage : A cohort study
(
- Contribution to journal › Article
-
Mark
A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer
(
- Contribution to journal › Article
- 2011
-
Mark
Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: An analysis of 215 cases from the Malmo Diet and Cancer Study
(
- Contribution to journal › Article
-
Mark
RBM3-Regulated Genes Promote DNA Integrity and Affect Clinical Outcome in Epithelial Ovarian Cancer.
(
- Contribution to journal › Article
-
Mark
Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer.
(
- Contribution to journal › Article
- 2010
-
Mark
Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer
(
- Contribution to journal › Article
- 2009
-
Mark
Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer.
2009) In Modern Pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 22. p.1564-1574(
- Contribution to journal › Article
- « previous
- 1
- 2
- 3
- 4
- next »